Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
Holders of notes subject to the tender offer who validly tendered, and did not validly withdraw, their notes on or before
Title of Security |
CUSIP No. |
Acceptance |
Reference |
Reference |
Fixed |
Total |
4.150% Notes due 2059 |
532457 BU1 |
1(3) |
2.375% due |
1.865% |
80 bps |
|
3.950% Notes due 2049 |
532457 BT4 |
2(4) |
2.375% due |
1.865% |
70 bps |
|
7.125% Notes due 2025 |
532457 AM0 |
3 |
0.750% due |
0.820% |
15 bps |
|
6.770% Notes due 2036 |
532457 AP3 |
4 |
1.250% due |
1.321% |
105 bps |
|
5.950% Notes due 2037 |
532457 BC1 |
5 |
1.750% due |
1.816% |
55 bps |
|
5.550% Notes due 2037 |
532457 BA5 |
6 |
1.750% due |
1.816% |
50 bps |
|
5.500% Notes due 2027 |
532457 AZ1 |
7 |
0.750% due |
0.820% |
40 bps |
|
4.650% Notes due 2044 |
532457 BG2 |
8 |
1.750% due |
1.816% |
75 bps |
|
3.950% Notes due 2047 |
532457 BR8 |
9 |
2.375% due |
1.865% |
70 bps |
|
3.875% Notes due 2039 |
532457 BS6 |
10 |
1.750% due |
1.816% |
45 bps |
|
3.700% Notes due 2045 |
532457 BJ6 |
11 |
2.375% due |
1.865% |
65 bps |
|
3.375% Notes due 2029 |
532457 BV9 |
12 |
1.250% due |
1.321% |
15 bps |
|
3.100% Notes due 2027 |
532457 BP2 |
13 |
0.750% due |
0.820% |
35 bps |
|
2.750% Notes due 2025 |
532457 BH0 |
14 |
0.750% due |
0.820% |
0 bps |
|
2.350% Notes due 2022 |
532457 BQ0 |
15 |
1.750% due |
0.070% |
10 bps |
|
(1) Per |
(2) The applicable total consideration includes an early tender premium of |
(3) |
(4) Lilly has removed the previously announced note cap setting forth the maximum principal amount of 3.950% Notes due 2049 that |
All payments for notes accepted for purchase in connection with the early tender date will also include accrued and unpaid interest on the principal amount of such notes to, but excluding, the initial settlement date, which is currently expected to be
Holders of notes subject to the tender offer who validly tender and do not validly withdraw their notes after the early tender date will, if such notes are accepted by
The tender offer is scheduled to expire at
In accordance with the terms of the tender offer, the withdrawal date was
The tender offer is being conducted on the terms and subject to the conditions set forth in the Offer to Purchase, dated
Requests for documents relating to the tender offer may be directed to
This press release is for informational purposes only and is not an offer to purchase, the solicitation of an offer to sell any notes. The tender offer is being made only pursuant to the Offer to Purchase and the information in this press release is qualified by reference to the Offer to Purchase. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of
In addition, this press release is not an offer to sell or the solicitation of an offer to buy any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any such securities will be offered only by means of a prospectus, including a prospectus supplement relating to such securities, meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the timing, terms, conditions, and other aspects of the tender offer and reflects
Refer to: |
Molly McCully; mccully_molly@lilly.com; (317) 478-5423 (Media) |
Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-301381933.html
SOURCE